Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
Adjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia
Sponsor: Ortho-McNeil Neurologics, Inc.
Listed as NCT00176423, this PHASE4 trial focuses on Schizoaffective Disorder and Schizophrenia and remains completed. Sponsored by Ortho-McNeil Neurologics, Inc., it has been updated 8 times since 2002, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
May 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ortho-McNeil Neurologics, Inc.
- Stanley Medical Research Institute
- University of Maryland, Baltimore
For direct contact, visit the study record on ClinicalTrials.gov .